| Autor: |
Sanz Herrero, F., Puchades Gimeno, F., Ortega García, P., Ferrer Gómez, C., Ocete Mochón, M. D., García Deltoro, M. |
| Předmět: |
|
| Zdroj: |
Journal of Internal Medicine; Feb2021, Vol. 289 Issue 2, p259-263, 5p |
| Abstrakt: |
Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study Methods Methylprednisolone treatment was introduced in our local treatment protocol on 27 March 2020 in addition to tocilizumab (administered as a single 400 mg dose) for those patients who display one of the following criteria: PaO SB 2 sb /FiO SB 2 sb < 300, SpO SB 2 sb < 92 (room air), tachypnea, and high ferritin levels. We compared those patients' treatment consecutively with or without methylprednisolone in two different periods of time (before and after the new treatment protocol began). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text